The failing diabetic heart: Focus on diastolic left ventricular dysfunction

被引:33
作者
van Heerebeek, Loek [1 ]
Somsen, Aernout [1 ]
Paulus, Walter J. [1 ]
机构
[1] Vrije Univ Amsterdam, Med Ctr, Physiol Lab, NL-1081 BT Amsterdam, Netherlands
关键词
GLYCATION END-PRODUCTS; PROTEIN-KINASE-G; ANGIOTENSIN-II; NITRIC-OXIDE; ENDOTHELIAL DYSFUNCTION; NORMOTENSIVE PATIENTS; MYOCARDIAL FIBROSIS; NATRIURETIC PEPTIDE; DRUG INSIGHT; FAILURE;
D O I
10.1007/s11892-009-0014-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetes mellitus (DM) is highly prevalent and is an important risk factor for congestive heart failure (HF). Increased left ventricular (LV) diastolic stiffness is recognized as the earliest manifestation of DM-induced LV dysfunction, but its pathophysiology remains incompletely understood. Mechanisms whereby DM increases LV diastolic stiffness differ between HF with normal LV ejection fraction (EF) (HFNEF) and HF with reduced LVEF (HFREF). In diabetic HFREF, fibrosis and deposition of advanced glycation end products (AGEs) are the most important contributors to high LV diastolic stiffness, whereas in diabetic HFNEF, elevated resting tension of hypertrophied cardiomyocytes is the most important contributor to high LV diastolic stiffness. As HF mortality remains high in DM despite proven efficacy of current treatments, better understanding of the pathophysiology of high LV diastolic stiffness could be beneficial for novel therapeutic strategies.
引用
收藏
页码:79 / 86
页数:8
相关论文
共 49 条
[31]   Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface [J].
McKinsey, Timothy A. ;
Kass, David A. .
NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (08) :617-635
[32]   Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility [J].
Nagendran, Jayan ;
Archer, Stephen L. ;
Soliman, Daniel ;
Gurtu, Vikram ;
Moudgil, Rohit ;
Haromy, Alois ;
St. Aubin, Chantal ;
Webster, Linda ;
Rebeyka, Ivan M. ;
Ross, David B. ;
Light, Peter E. ;
Dyck, Jason R. B. ;
Michelakis, Evangelos D. .
CIRCULATION, 2007, 116 (03) :238-248
[33]   Should angiotensin II receptor blockers and statins be combined? [J].
Nickenig, G .
CIRCULATION, 2004, 110 (08) :1013-1020
[34]   Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide/cGMP signaling and endothelial dysfunction [J].
Oelze, M ;
Mollnau, H ;
Hoffmann, N ;
Warnholtz, A ;
Bodenschatz, M ;
Smolenski, A ;
Walter, U ;
Skatchkov, M ;
Meinertz, T ;
Munzel, T .
CIRCULATION RESEARCH, 2000, 87 (11) :999-1005
[35]   Epidemiology of diastolic heart failure [J].
Owan, TE ;
Redfield, MM .
PROGRESS IN CARDIOVASCULAR DISEASES, 2005, 47 (05) :320-332
[36]   Role of peroxynitrite in the pathogenesis of cardiovascular complications of diabetes [J].
Pacher, P ;
Szabó, C .
CURRENT OPINION IN PHARMACOLOGY, 2006, 6 (02) :136-141
[37]   Metabolic risk factors, endothelial dysfunction, and erectile dysfunction in men with diabetes [J].
Palumbo, Pasquale J. .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2007, 334 (06) :466-480
[38]   Nitric oxide's role in the heart: control of beating or breathing? [J].
Paulus, WJ ;
Bronzwaer, JGF .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2004, 287 (01) :H8-H13
[39]   Burden of systolic and diastolic ventricular dysfunction in the community - Appreciating the scope of the heart failure epidemic [J].
Redfield, MM ;
Jacobsen, SJ ;
Burnett, JC ;
Mahoney, DW ;
Bailey, KR ;
Rodeheffer, RJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (02) :194-202
[40]   NEW TYPE OF CARDIOMYOPATHY ASSOCIATED WITH DIABETIC GLOMERULOSCLEROSIS [J].
RUBLER, S ;
YUCEOGLU, YZ ;
KUMRAL, T ;
GRISHMAN, A ;
BRANWOOD, AW ;
DLUGASH, J .
AMERICAN JOURNAL OF CARDIOLOGY, 1972, 30 (06) :595-&